{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:10:28Z","timestamp":1789708228568,"version":"4.0.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.taap.2023.116541","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T11:24:16Z","timestamp":1683199456000},"page":"116541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["In silico and in vitro screening for carcinogenic potential of angiotensin-converting enzyme inhibitors and their degradation impurities"],"prefix":"10.1016","volume":"469","author":[{"given":"Katarzyna","family":"Regulska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Matera-Witkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Miko\u0142ajczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata J.","family":"Stanisz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2023.116541_bb0005","series-title":"\u201cPopularize Artificial Intelligence 2013\u201d December 5th 2013, Turin, Italy Published on CEUR Workshop Proceedings Vol-1107","article-title":"VEGA-QSAR: AI inside a platform for predictive toxicology. Proceedings of the workshop","author":"Benfenati","year":"2013"},{"key":"10.1016\/j.taap.2023.116541_bb0010","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/17425255.2020.1785428","article-title":"In silico models for genotoxicity and drug regulation","volume":"16","author":"Benigni","year":"2020","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.taap.2023.116541_bb0015","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s10549-014-2870-5","article-title":"Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer","volume":"144","author":"Boudreau","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.taap.2023.116541_bb0020","first-page":"545","article-title":"Life after Cancer epidemiology (LACE) study: a cohort of early stage breast cancer survivors (United States)","volume":"16","author":"Caan","year":"2005","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.taap.2023.116541_bb0025","author":"Datapharm lLtd electronic medicines compendium"},{"key":"10.1016\/j.taap.2023.116541_bb0030","series-title":"Overview and Recommendations. EMA\/526934\/2019","article-title":"Lessons learnt from presence of N-nitrosamine impurities in sartan medicines","author":"European Medicines Agency","year":"2020"},{"key":"10.1016\/j.taap.2023.116541_bb0035","series-title":"The Use of Computational Methods in the Toxicological Assessment of Chemicals in Food: Current Status and Future Prospects","author":"Fuart-Gatnik","year":"2011"},{"key":"10.1016\/j.taap.2023.116541_bb0040","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.fct.2018.04.024","article-title":"In silico genotoxicity and carcinogenicity prediction for food-relevant secondary plant metabolites","volume":"116","author":"Gl\u00fcck","year":"2018","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.taap.2023.116541_bb0045","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1053\/euhj.2001.2729","article-title":"Antihypertensive therapy and the risk of malignancies","volume":"22","author":"Grossman","year":"2001","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.taap.2023.116541_bb0050","article-title":"Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study","volume":"363","author":"Hicks","year":"2018","journal-title":"BMJ."},{"key":"10.1016\/j.taap.2023.116541_bb0055","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1177\/0300985812450727","article-title":"History of chronic toxicity and animal carcinogenicity studies for pharmaceuticals","volume":"50","author":"Jacobs","year":"2013","journal-title":"Vet. Pathol."},{"key":"10.1016\/j.taap.2023.116541_bb0060","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cbi.2018.11.011","article-title":"Review of the evidence for thresholds for DNA-reactive and epigenetic experimental chemical carcinogens","volume":"301","author":"Kobets","year":"2019","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.taap.2023.116541_bb0065","doi-asserted-by":"crossref","first-page":"9429","DOI":"10.3390\/ijerph18189429","article-title":"Drugs becoming generics-the impact of Genericization on the market performance of antihypertensive active pharmaceutical ingredients","volume":"18","author":"Kov\u00e1cs","year":"2021","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.taap.2023.116541_bb0070","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.120.006687","article-title":"Use of ACE (angiotensin-converting enzyme) inhibitors and risk of lung Cancer: a Nationwide nested case-control study","volume":"14","author":"Kristensen","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes."},{"key":"10.1016\/j.taap.2023.116541_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6904-6-1","article-title":"Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilat","volume":"6","author":"Levitt","year":"2006","journal-title":"BMC Clin. Pharmacol."},{"key":"10.1016\/j.taap.2023.116541_bb0080","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3390\/cancers12030747","article-title":"Association between angiotensin-converting enzyme inhibitors and lung Cancer-a Nationwide, population-based, propensity score-matched cohort study","volume":"12","author":"Lin","year":"2020","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.taap.2023.116541_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2013.00038","article-title":"Lazar: a modular predictive toxicology framework","volume":"4","author":"Maunz","year":"2013","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.taap.2023.116541_bb0090","author":"National Library of Medicine"},{"key":"10.1016\/j.taap.2023.116541_bb0095","series-title":"Test No. 487: In Vitro Mammalian Cell Micronucleus Test, OECD Guidelines for the Testing of Chemicals, Section 4","author":"OECD","year":"2016"},{"key":"10.1016\/j.taap.2023.116541_bib166","doi-asserted-by":"crossref","first-page":"104326","DOI":"10.1016\/j.phrs.2019.104326","article-title":"Beyond the boundaries of cardiology: Still untapped anticancer properties of the cardiovascular system-related drugs","volume":"147","author":"Regulska","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.taap.2023.116541_bb0120","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.drudis.2019.03.010","article-title":"Can cardiovascular drugs support cancer treatment? The rationale for drug repurposing","volume":"24","author":"Regulska","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.taap.2023.116541_bb0100","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1208\/s12249-013-0010-x","article-title":"Optimization of storage and manufacture conditions for imidapril hydrochloride in solid state as a way to reduce costs of antihypertensive therapy","volume":"14","author":"Regulska","year":"2013","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.taap.2023.116541_bb0105","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ijpharm.2013.09.002","article-title":"Is there any association between imidapril hydrochloride stability profile under dry air conditions and cancer initiation?","volume":"456","author":"Regulska","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.taap.2023.116541_bb0110","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.drudis.2014.06.026","article-title":"How to design a potent, specific, and stable angiotensin-converting enzyme inhibitor","volume":"19","author":"Regulska","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.taap.2023.116541_bb0115","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.rpor.2014.04.004","article-title":"The mutagenicity analysis of imidapril hydrochloride and its degradant, diketopiperazine derivative, nitrosation mixtures by in vitro Ames test with two strains of salmonella typhimurium","volume":"19","author":"Regulska","year":"2014","journal-title":"Rep Pract Oncol Radiother."},{"key":"10.1016\/j.taap.2023.116541_bb0125","first-page":"116","article-title":"Genotoxic impurities in pharmaceutical products - regulatory, toxicological and pharmaceutical considerations","volume":"90","author":"Regulska","year":"2021","journal-title":"J. Med. Sci."},{"issue":"10","key":"10.1016\/j.taap.2023.116541_bb0130","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.3390\/pharmaceutics13101600","article-title":"Solid-state stability profiling of Ramipril to optimize its quality efficiency and safety","volume":"13","author":"Regulska","year":"2021","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.taap.2023.116541_bb0135","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.3390\/app13042358","article-title":"The degradation product of Ramipril is potentially carcinogenic","volume":"13","author":"Regulska","year":"2023","journal-title":"Genotoxic Mutag. Appl Sci."},{"key":"10.1016\/j.taap.2023.116541_bb0140","first-page":"116","article-title":"Sustainable synthesis, in silico evaluation of potential toxicity and environmental fate, antioxidant and UV-filtering\/photostability activity of phenolic-based thiobarbituric derivatives","volume":"15","author":"Rioux","year":"2022","journal-title":"GCLR."},{"issue":"4","key":"10.1016\/j.taap.2023.116541_bb0145","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202100435","article-title":"Risk assessment for nitrosated pharmaceuticals: a future perspective in drug development","volume":"355","author":"Schmidtsdorff","year":"2022","journal-title":"Arch Pharm (Weinheim)."},{"key":"10.1016\/j.taap.2023.116541_bb0150","first-page":"563","article-title":"Prognostic factors for early relapse in non-metastatic triple negative breast cancer - real world data","volume":"26","author":"Soares","year":"2021","journal-title":"Rep Pract Oncol Radiother."},{"key":"10.1016\/j.taap.2023.116541_bb0155","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1200\/JCO.2012.43.9190","article-title":"Use of \u03b2-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study","volume":"31","author":"S\u00f8rensen","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.taap.2023.116541_bb0160","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejphar.2016.12.031","article-title":"Unknown face of known drugs - what else can we expect from angiotensin converting enzyme inhibitors?","volume":"797","author":"Wzgarda","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.taap.2023.116541_bb0165","first-page":"1007","article-title":"Thermo-, radio- and photostability of perindopril tert-butyloamine in the solid state. Comparison to other angiotensin converting enzyme inhibitors. Iran","volume":"16","author":"Wzgarda","year":"2017","journal-title":"J. Pharm. Res."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X23001801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X23001801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:01:32Z","timestamp":1758574892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X23001801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":34,"alternative-id":["S0041008X23001801"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2023.116541","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In silico and in vitro screening for carcinogenic potential of angiotensin-converting enzyme inhibitors and their degradation impurities","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2023.116541","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116541"}}